JAMA Network Home
Sign In
Editor's Pick Original Investigation

Efficacy and Safety of Semaglutide According to Frailty Status

JAMA Cardiology 10.1001/jamacardio.2026.3566

September 16, 2026 at 11:00 AM EDT

Read the full article

This study found that semaglutide demonstrated beneficial effects on a broad range of clinical outcomes in SELECT, without detectable heterogeneity by baseline FI. Benefits of semaglutide on health-related quality of life appeared greater with higher FI.

Corresponding Author: John W. Ostrominski, MD, MPH, Cardiovascular Division, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (jostrominski@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2026.3566?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091626

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks